Related to Shire, Shionogi Ink Co-Development Agreement for ADHD Drugs in Japan

• Companies Step In to Fill Gap in Enzyme Replacement Therapy for Gaucher’s
  Shortage could lead to more choices for patients sooner than expected.
  
• Big Pharma Adopting Orphan Drug Strategy
  Potential for profitability in small markets is beginning to lure companies away from the failing blockbluster model.
  
• Japan Disaster Renews Interest in Antiradiation Drug Development
  BARDA's flexibility in dealing with industry is improving investor's confidence in biodefense.
  
• Asia’s Emerging Markets Catching Up to the U.S. and Europe in Terms of Innovation
  Countries like China and Korea are growing to be more than just manufacturing hubs.
  
• Brain Drain and Need for New Infrastructure Loom as Challenges to Post-Quake Japan
  Another concern, five months after the disaster, is restrictions on electrical usage.
  
• U.S. Stem Cell Companies Find Partners and Revenues Beyond the Water’s Edge
  Firms find it easier to navigate regulatory requirements in Asia as well as Europe.
  
• Japan and Australia to Institute Changes to Patent System This Year
  Amendments in Japan take effect in April, and approval of the Australian bill is expected mid-year.
  
• This Month Last Year: Shire and Thermo Fisher’s Acquisitions and Geron’s hESC Plans
  While Geron’s good news in May 2011 didn’t last long, Shire and Thermo hope their moves strengthen their businesses.